Seikagaku Corporation
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
10
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 16 to 28, 2027 · next Jan 16
- 1 fee due Feb 28, 2027The maintenance fee for Composition for Treating Joint Disease and Kit Containing Same (US 11,738,040) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 3 fees due Mar 5 to 24, 2027 · next Mar 5
- 1 fee due Apr 10, 2027The maintenance fee for Agent for improving ocular subjective symptoms and method thereof (US 11,779,593) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
- 2 fees due Oct 2 to 16, 2027 · next Oct 2
Recent changes
- 2 of the patents on this record were granted since Aug 24, 2026
- Nov 3 US 12,782,358 Reagent for Measuring B-Glucan, Method for Producing Same and Use Thereof
- Sep 29 US 12,748,115 A Method for Producing an Exdotoxin Measuring Agent
- 1 term has ended since Aug 24, 2026
- Oct 12 US 8,969,319 Agent for Applying to Mucosa and Method for the Production Thereof · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,927,837 | Modified chondroitin synthase polypeptide and crystal thereof In force · USPTO record | In force | USPTO record | |
| US 9,301,972 | Hyaluronic acid derivatives In force · USPTO record | In force | USPTO record | |
| US 9,616,087 | Pharmaceutical agent having long-lasting effect of treating arthritic disorders In force · USPTO record | In force | USPTO record | |
| US 8,283,145 | Chondroitin-producing bacterium and method of producing chondroitin In force · USPTO record | In force | USPTO record | |
| US 8,889,652 | Pharmaceutical agent having long-lasting effect of treating arthritic disorders In force · USPTO record | In force | USPTO record | |
| US 8,557,986 | Method of producing polysaccharide derivatives In force · USPTO record | In force | USPTO record | |
| US 8,529,519 | Tight-sealing cap for liquid drug-expelling part In force · USPTO record | In force | USPTO record | |
| US 10,420,795 | Pharmaceutical composition for relieving pain In force · USPTO record | In force | USPTO record | |
| US 9,579,342 | Pharmaceutical composition for relieving pain In force · USPTO record | In force | USPTO record | |
| US 8,828,969 | Pharmaceutical composition for relieving pain In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 66: 2 patents in force now held by others · 84 lapsed for an unpaid fee · 73 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 15 abandoned · 45 no status recorded